Your browser doesn't support javascript.
loading
Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease.
Zimmerman, Ofer; Rösler, Berenice; Zerbe, Christa S; Rosen, Lindsey B; Hsu, Amy P; Uzel, Gulbu; Freeman, Alexandra F; Sampaio, Elizabeth P; Rosenzweig, Sergio D; Kuehn, Hye Sun; Kim, Tiffany; Brooks, Kristina M; Kumar, Parag; Wang, Xiaowen; Netea, Mihai G; van de Veerdonk, Frank L; Holland, Steven M.
Afiliação
  • Zimmerman O; Immunopathogenesis Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Immunology, National Institutes of Health, Bethesda, Maryland.
  • Rösler B; Department of Internal Medicine and Radboud Center for Infectious diseases (RCI), Radboud University Medical Centre, Nijmegen, the Netherlands.
  • Zerbe CS; Immunopathogenesis Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Immunology, National Institutes of Health, Bethesda, Maryland.
  • Rosen LB; Immunopathogenesis Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Immunology, National Institutes of Health, Bethesda, Maryland.
  • Hsu AP; Immunopathogenesis Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Immunology, National Institutes of Health, Bethesda, Maryland.
  • Uzel G; Immunopathogenesis Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Immunology, National Institutes of Health, Bethesda, Maryland.
  • Freeman AF; Immunopathogenesis Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Immunology, National Institutes of Health, Bethesda, Maryland.
  • Sampaio EP; Immunopathogenesis Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Immunology, National Institutes of Health, Bethesda, Maryland.
  • Rosenzweig SD; Immunology Service, Department of Laboratory Medicine, National Institutes Clinical Center, National Institutes of Health, Bethesda, Maryland.
  • Kuehn HS; Immunology Service, Department of Laboratory Medicine, National Institutes Clinical Center, National Institutes of Health, Bethesda, Maryland.
  • Kim T; Department of Pharmacy, Clinical Center, National Institutes of Health, Bethesda, Maryland.
  • Brooks KM; Department of Pharmacy, Clinical Center, National Institutes of Health, Bethesda, Maryland.
  • Kumar P; Department of Pharmacy, Clinical Center, National Institutes of Health, Bethesda, Maryland.
  • Wang X; Department of Internal Medicine and Radboud Center for Infectious diseases (RCI), Radboud University Medical Centre, Nijmegen, the Netherlands.
  • Netea MG; Department of Dermatology, Peking University First Hospital, Beijing, China.
  • van de Veerdonk FL; Department of Internal Medicine and Radboud Center for Infectious diseases (RCI), Radboud University Medical Centre, Nijmegen, the Netherlands.
  • Holland SM; Department of Internal Medicine and Radboud Center for Infectious diseases (RCI), Radboud University Medical Centre, Nijmegen, the Netherlands.
Open Forum Infect Dis ; 4(4): ofx202, 2017.
Article em En | MEDLINE | ID: mdl-29226168
Heterozygous STAT1 gain-of-function (GOF) mutations are associated with chronic mucocutaneous candidiasis and a broad spectrum of infectious, inflammatory, and vascular manifestations. We describe therapeutic failures with the Janus Kinase (JAK) inhibitor ruxolitinib in 2 STAT1 GOF patients with severe invasive or cutaneous fungal infections.
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Risk_factors_studies Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Risk_factors_studies Idioma: En Ano de publicação: 2017 Tipo de documento: Article